June 20, 2018

Cerebral Therapeutics Raises Series A Financing to Advance Clinical-Stage Drug-Device Combination Therapy for Adult Refractory Epilepsy

June 20, 2018/ Distill

Financing Led by Granite Point Capital and Vivo Capital
Cerebral Therapeutics Adds Three New Members to its Board of Directors

Aurora, CO., June 20, 2018

Read Full Article

October 13, 2017

Flowonix Medical and Cerebral Therapeutics Announce Fifth Implant of First-of-a-Kind Implantable Drug Therapy to Treat Patients with Refractory Epilepsy

October 13, 2017/ Distill

Read Full Article

March 01, 2017

World-First Clinical Trial Delivering Medication Directly Into The Brain For Patients With Refractory Epilepsy

March 01, 2017/ Distill

Read Full Article

October 01, 2015

Flowonix, Cerebral Therapeutics ink deal to develop direct-to-brain drug delivery system

October 01, 2015/ Distill

Read Full Article

July 30, 2015

David Jenkins Joins the Cerebral Therapeutics Team

July 30, 2015/ Distill

In July 2015 David Jenkins joined the board of Cerebral Therapeutics, Inc. David brings extensive knowledge and experience in the areas of corporate strategy and product development. David has been successful bringing companies from the entrepreneurial stage to market leaders for over 30 years.